Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
A run of bad news leaves investors questioning Wave Life Sciences’ ability to deliver on its promises.
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Second Sight’s second product might lead the company to second place in the market.
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.